X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs AUROBINDO PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA AUROBINDO PHARMA SUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 27.8 19.6 141.7% View Chart
P/BV x 2.9 3.9 75.7% View Chart
Dividend Yield % 0.4 0.3 133.3%  

Financials

 SUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
SUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs701809 86.6%   
Low Rs433504 86.0%   
Sales per share (Unadj.) Rs110.4281.1 39.3%  
Earnings per share (Unadj.) Rs11.041.4 26.5%  
Cash flow per share (Unadj.) Rs17.250.9 33.9%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.4 92.7%  
Book value per share (Unadj.) Rs158.8199.4 79.7%  
Shares outstanding (eoy) m2,399.26585.88 409.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.3 219.8%   
Avg P/E ratio x51.615.9 325.3%  
P/CF ratio (eoy) x32.912.9 255.0%  
Price / Book Value ratio x3.63.3 108.4%  
Dividend payout %18.26.0 301.4%   
Avg Mkt Cap Rs m1,360,021384,630 353.6%   
No. of employees `00017.817.3 102.6%   
Total wages/salary Rs m53,67121,308 251.9%   
Avg. sales/employee Rs Th14,890.99,500.7 156.7%   
Avg. wages/employee Rs Th3,017.11,229.4 245.4%   
Avg. net profit/employee Rs Th1,480.61,397.9 105.9%   
INCOME DATA
Net Sales Rs m264,895164,666 160.9%  
Other income Rs m8,3881,020 822.5%   
Total revenues Rs m273,282165,686 164.9%   
Gross profit Rs m56,08137,718 148.7%  
Depreciation Rs m14,9985,580 268.8%   
Interest Rs m5,176777 665.9%   
Profit before tax Rs m44,29532,380 136.8%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4528,183 103.3%   
Profit after tax Rs m26,33824,229 108.7%  
Gross profit margin %21.222.9 92.4%  
Effective tax rate %19.125.3 75.5%   
Net profit margin %9.914.7 67.6%  
BALANCE SHEET DATA
Current assets Rs m316,359121,878 259.6%   
Current liabilities Rs m198,64386,806 228.8%   
Net working cap to sales %44.421.3 208.6%  
Current ratio x1.61.4 113.4%  
Inventory Days Days95130 73.0%  
Debtors Days Days10868 157.5%  
Net fixed assets Rs m213,17881,037 263.1%   
Share capital Rs m2,399586 409.5%   
"Free" reserves Rs m378,606116,218 325.8%   
Net worth Rs m381,006116,804 326.2%   
Long term debt Rs m17,7214,512 392.8%   
Total assets Rs m643,028211,052 304.7%  
Interest coverage x9.642.7 22.4%   
Debt to equity ratio x00 120.4%  
Sales to assets ratio x0.40.8 52.8%   
Return on assets %4.911.8 41.4%  
Return on equity %6.920.7 33.3%  
Return on capital %10.027.4 36.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81680,727 50.6%   
Fx outflow Rs m30,14334,700 86.9%   
Net fx Rs m10,67346,027 23.2%   
CASH FLOW
From Operations Rs m39,07219,548 199.9%  
From Investments Rs m-33,708-19,570 172.2%  
From Financial Activity Rs m-15,3938,642 -178.1%  
Net Cashflow Rs m-7,3598,922 -82.5%  

Share Holding

Indian Promoters % 63.7 54.1 117.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.0 64.5%  
FIIs % 23.0 27.7 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.2 81.4%  
Shareholders   133,026 69,601 191.1%  
Pledged promoter(s) holding % 0.5 8.6 6.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Fall Amid Global Selloff; Sensex Down Over 400 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Barring oil & gas sector, all sectoral indices are trading in red with realty stocks.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 25, 2019 02:55 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS